AI-based oncology therapy developer Signet Therapeutics has received FDA approval for its IND application for sigx1094, a targeted drug for diffuse gastric cancer (DGC). Following the approval, the company is prepared to commence Phase I clinical trials to assess the treatment's safety and efficacy against DGC and other advanced solid tumors.
Sigx1094 was developed using Signet's proprietary organoid disease model platform and AI in collaboration with AI-powered R&D platform company XtalPi. Organoids refer to 3D miniaturized versions of organs or tissues derived from stem cells. They can mimic an organ's key function, structure, and biological complexity, aiding in drug development and clinical trials.
Signet Therapeutics focuses on developing targeted oncology therapeutics, leveraging advanced AI technology and disease models to enhance drug discovery and development processes. The company’s approach uses real-world cancer genomics data to create 3D organoid models, providing more clinically relevant data.
By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.